Zevamab
Zevamab Uses, Dosage, Side Effects, Food Interaction and all others data.
Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light chains of 213 amino acids each.
Ibritumomab is a murine monoclonal antibody against CD20 that has been radiolabeled with yttrium-90.
Trade Name | Zevamab |
Generic | Ibritumomab tiuxetan |
Ibritumomab tiuxetan Other Names | Ibritumomab, Ibritumomab tiuxetan, mAb Murine (IGG1) Anti P19437 (CD20_MOUSE) |
Type | |
Formula | C6382H9830N1672O1979S54 |
Weight | 143375.5 Da |
Groups | Approved, Investigational |
Therapeutic Class | |
Manufacturer | |
Available Country | Colombia |
Last Updated: | September 19, 2023 at 7:00 am |
![Zevamab Zevamab](https://www.medicinesfaq.com/media/png/zevamab.png)
Uses
Zevamab is a monoclonal anti-CD20 antibody used to treat B-cell non-Hodgkin's lymphoma via a conjugated radioactive isotope.
For treatment of non-Hodgkin's lymphoma
Zevamab is also used to associated treatment for these conditions: Follicular Non-Hodgkin's Lymphoma, Follicular Non-Hodgkin's Lymphoma Refractory
How Zevamab works
The Fab segment of the antibody targets the CD20 epitope on B-cells, allowing the radioactive yttrium to destroy the cell via production of beta particles.
Food Interaction
- Avoid herbs and supplements with anticoagulant/antiplatelet activity. Individuals taking these herbs/supplements while taking ibritumomab tiuxetan should be monitored for thrombocytopenia more frequently. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.
Volume of Distribution
Binding observed on lymphoid cells of the bone marrow, lymph node, thymus, red and white pulp of the spleen, lymphoid follicles of the tonsil, and lymphoid nodules of other organs (e.g., large and small intestines)
Half Life
0.8 hours (mammalian reticulocytes, in vitro)
Clearance
Approximately 7.2% of injected dose of yttrium Y 90 ibritumomab tiuxetan is excreted in urine within 7 days.
Innovators Monograph
You find simplified version here Zevamab